Nyxoah SA (NYXH)

Market Cap	292.88M
Revenue (ttm)	4.72M
Net Income (ttm)	-75.35M
Shares Out	37.43M
EPS (ttm)	-2.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,086
Open	7.76
Previous Close	7.75
Day's Range	7.71 - 7.86
52-Week Range	5.55 - 11.87
Beta	0.67
Analysts	Strong Buy
Price Target	14.50 (+87.58%)
Earnings Date	Aug 5, 2025

About NYXH

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jul 2, 2021
• Employees: 184
• Stock Exchange: NASDAQ
• Ticker Symbol: NYXH
• Website: https://www.nyxoah.com

Financial Performance

In 2024, Nyxoah's revenue was 4.52 million, an increase of 3.98% compared to the previous year's 4.35 million. Losses were -59.24 million, 37.1% more than in 2023.

Financial numbers in EUR

Analyst Forecast

According to 4 analysts, the average rating for NYXH stock is "Strong Buy." The 12-month stock price forecast is $14.5, which is an increase of 87.58% from the latest price.

Price Target

$14.5

(87.58% upside)

Analyst Consensus: Strong Buy